期刊文献+

不同化疗方案治疗晚期卵巢癌的效果 被引量:3

Different chemotherapy regimens for advanced ovarian cancer
下载PDF
导出
摘要 目的研究不同化疗方式治疗病情处于晚期阶段的卵巢癌疾病患者的临床效果。方法选取本院2016年1月至2017年1月收治并确诊为晚期卵巢癌的患者40例作为研究对象,并将其随机分为观察组以及对照组,每组20例。观察组采用腹腔热灌注联合静脉化疗进行治疗,对照组采用单纯静脉化疗治疗,对比两组临床治疗效果。结果观察组总控制率为80.0%,对照组总控制率为55.0%,差异具有统计学意义(P〈0.05)。结论腹腔热灌注联合静脉化疗治疗病情处于晚期阶段的卵巢癌疾病患者临床效果明显。 Objective To study the clinical effects of different chemotherapy treatments for patients with advanced stage of ovarian cancer. Methods 40 patients with advanced ovarian cancer diagnosed and treated at our hospital from January, 2016 to January, 2017 were selected, and were randomly divided into an observation group and a control group, 20 cases for each group. The observation group were treated with intrapedtoneal heat perfusion and intravenous chemotherapy, and the control group with intravenous chemotherapy. The treatment effects were compared between these two groups. Results The total control rate was 80.0% in the observation group, and was 55.0% in the control group, with a statistical difference (P 〈 0.05). Conclusion Peritoneal heat perfusion combined with intravenous chemotherapy for patients with advanced stage of ovarian cancer is very effective.
作者 郭靖 Guo Jing(Department of Obstetrics and Gynecology, Wuzhou People's Hospital, wuzhou 543000, Chin)
出处 《国际医药卫生导报》 2018年第12期1817-1819,共3页 International Medicine and Health Guidance News
关键词 不同化疗方案 晚期 卵巢癌 效果 Different chemotherapy regimens Advanced Ovarian cancer Effect
  • 相关文献

参考文献9

二级参考文献99

  • 1黄赞松,向发良,周喜汉,黄衍强,邓志华,仇仪英.苦参素对肝癌细胞HepG2细胞增殖和MicroRNA-122、MicroRNA-21表达的影响[J].中国老年学杂志,2014,34(11):3079-3081. 被引量:21
  • 2王晓晖,周景俭,胡文娟.紫杉醇联合顺铂化疗晚期卵巢癌24例效果分析[J].环球中医药,2013,6(S1):78-78. 被引量:4
  • 3蔡永,贾松娟,杜小彬.真武汤化裁治疗恶性腹水71例[J].江苏中医药,2006,27(8):30-30. 被引量:19
  • 4Hoff PM,Saad ED,Costa F,et al. Literature review and practical aspects on the management of Lobaplatin-associ- ated toxicity [J]. Clin Colorectal Cancer,2012,11 (2) :93- 100.
  • 5Edwards IR,Aronson JK. Adverse drug reactions:definitions, diagnosis,and management [J]. The Lancet,2000,356(8237) : 1255-1259.
  • 6Edeline J, Boucher E, Rolland Y, et al. Comparison of tu- mor response by response evaluation criteria in solid tu- mors (RECIST) and modified RECIST in patients treated with sorafeoib for hepatocellular carcinoma [J]. Cancer, 2012,118(1) : 147-156.
  • 7Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus Paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7):a randomised, multicentre,open,label,phase 3 trial [J]. Lancet Oncol, 2014,15(4) :396--405.
  • 8Pignata S,Seambia G, Ferrandina G,et al. Carboplatin plus Paclitaxel versus Carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovar- ian cancer:the MITO-2 randomized phase Ⅲ trial [J]. J Clin Oncol, 2011,29(27) : 3628-3635.
  • 9Dalton HJ,Yu X,Hu L,et al. An economic analysis of dose dense weekly Paclitaxel plus Carboplatin versus ev- ery-3-week Paclitaxel plus Carboplatin in the treatment of advanced ovarian cancer [J]. Gynecol Oncol,2012,124 (2) : 199-204.
  • 10Steffensen KD,Waldstrom M,Jakobsen A. The relation- ship of platinum resistance and ERCC1 protein expres- sion in epithelial ovarian cancer [J]. Int J Gynecol Can- cer,2009, 19(5) : 820-825.

共引文献57

同被引文献30

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部